Get started

Sidewaysbreakout

IOLCP Showing Change in Structure can go towards 52 Week HighNSE:IOLCP ...................................................................................................................... ...................................................................................................................... The Company’s turnover increased to ₹ 2,133 crore in FY24 from ₹ 983 crore in FY18 at a CAGR of 13.77% ...................................................................................................................... ...................................................................................................................... The share of regulated market sale has increased to ₹ 300 crore in FY24 from ₹100 crore in FY18 ...................................................................................................................... ...................................................................................................................... Increased contribution of non-Ibuprofen drugs from ₹35 crore in FY18 to ₹431 crore in FY24, showing a steady upward trend over the years ...................................................................................................................... ...................................................................................................................... Added more than 10 products since 2017 in APIs and chemical segments. The Company has recently commenced a new plant of Acetic Anhydride ...................................................................................................................... ...................................................................................................................... • The Indian API market is expected to grow at a CAGR of 13.7% over the four years. • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. • As the largest supplier of generic medicines, India manufactures around 60,000 different generic brands across 60 therapeutic categories. • In FY24 India saw a 4.12% increase in the total imports of bulk drugs and intermediates, amounting to ₹ 37,721.88 crore, compared to ₹ 36,229.15 crore in FY23. • Indian medicines are preferred worldwide due to their combination of low price and high quality, earning India the title of "pharmacy of the world." ...................................................................................................................... ...................................................................................................................... Positive factors • Strongly improving operating performance, resulting in growth of more than 15% in total operating income and sustained EBIDTA margin of more than 20%, on a sustained. • Diversifying product portfolio and reducing dependency on its main product Ibuprofen and ethyl acetate to below 65% in the overall revenue. • Improving total debt to gross cash accruals (TD/GCA) and TD to profit before interest, lease rentals, depreciation, and taxation (TD/PBILDT) to below unity. ...................................................................................................................... ...................................................................................................................... Established market position and diversified product offering The company was incorporated, 1986 with the commencement of business in chemical segment. In 2000, the company started production of Ibuprofen. IOLCPL is one of the largest manufacturers of Ibuprofen with significant global share and the company is backward integrated for manufacturing Ibuprofen. IOLCPL has a market presence across more than 50 countries with sales contribution from exports forming around 28% of total sales in FY24 (PY: 29%). The company’s overseas customers are spread across Switzerland, Bangladesh, Spain, Indonesia, Hungary, United Kingdom, Nepal, China, Turkey and Japan, among others. The company is one of the largest manufacturers of Ibuprofen (capacity of 12000 MTPA) and has the second largest manufacturing capacity (12000MTPA) for Iso Butyl Benzene (key raw material for Ibuprofen)
NSE:IOLCPLong
by iism-ExpertTrading
RUPA indicating is No More an Ordinary Underwear BrandNSE:RUPA Commenting on the financial performance Mr. Vikash Agarwal - Whole Time Director, said, “We are pleased to report a stable performance in Q1 FY25, though the industry continues to witness resistance to any price increase. We demonstrated steady improvements across key financial metrics. This quarter, we witnessed 8% rise in revenue, primarily driven by strong sales in our core product line. Our volume growth for the quarter reached 9%, supported by strong sales in the economy and athleisure segments. Our EBITDA saw a year-on-year increase of 59%, totaling Rs. 18.0 crores for the quarter, showcasing our commitment to cost management and operational efficiency. Operating margins also improved by 280 basis points compared to the same period last year. Furthermore, our net profit experienced substantial growth of 149%, reaching Rs. 10.5 crores for the quarter. This underscores the effectiveness of our financial strategies and the resilience of our business model. Net profit margins improved by 280 basis points during the quarter. Notably, our exports have shown progress, with a healthy 32% year-on-year growth, reaching Rs. 8 crores. This reflects our steady penetration into international markets. Revenue contribution from Modern Trade remains robust at 8% in Q1 FY25. The pilot project “Pragati’, which was launched last quarter, has received encouraging feedback from our distributors. We expect healthy expansion of the project going forward. Our cash flow from operations remains strong, generating Rs. 44 crores in Q1 FY25. We have made significant progress in reducing our debt, achieving a net debt-free status as at end of Q1 FY25. Our branding and advertising strategies accounted for 9% of revenues in Q1 FY25. Looking ahead, we are confident in achieving new business milestones and delivering innovative products to our diverse customer segments. Our customer-first approach will help us strengthen our position as an industry leader and contribute to our sustainable business model
NSE:RUPALong
by iism-ExpertTrading
HARSHA ENGINEERS INTERNATIONAL LTDCompany is almost debt free. Company has delivered good profit growth of 56.4% CAGR over last 5 years The combined share of operating losses at China and Romania came down significantly because of China reporting positive profit in Q4 FY 2024. However, Romania continued to report operating losses in Q4 FY 2024. ➢ While the demand situation in Europe both on the Wind as well as on the Industrial front remains subdued, our strategy in Romania is to improve product mix by increasing the share of cages, which is aimed at bringing Romania to Break-even level in FY 2025. ➢ Solar Business has reported a decent growth in top-line as well as profitability, on the back of a favourable renewable policy regime, with our strategy continued to be on limited capital allocation in this segment, but still allowing the same to operate in its natural tangent. ➢ The progress on our Greenfield project is satisfactory and is expected to commission in FY 2025. On a consolidated basis Q4 FY 2024 was the strongest quarter in the current fiscal FY 2024 reflecting an allround improvement in the top line as well as the EBITDA and PAT margins. The consolidated top line of Q4 FY 2024 has shown a growth of 17% over Q3 FY 2024 and 11% over Q4 FY 2023. The consolidated EBITDA of Q4 FY 2024 has also grown by 23% as compared to Q3 FY 2024 and 10% as compared to Q4 FY 2023. ➢ On full year basis, while consolidated top line of FY 2023-24 reflects a marginal growth over FY 2022-23, the EBITDA and PAT of FY 2024, though lower than FY 2023, are still reflecting a significant recovery as compared to H1 FY 2024 and are better than our expectations. ➢ The growth in Bushing business as well as additional demand growth due to China + 1 factor was in line with our expectations. The Progress on outsourcing projects (insourcing to outsourcing) was satisfactory, and the growth in Japan based customers’ segment, though slightly muted, has remained positive. ➢ The expected growth in large size bearing cages segment could not be achieved due to continued global slowdown in the Wind as well as Industrial Segment, but is expected to catch up next Fiscal.
NSE:HARSHALong
by iism-ExpertTrading
ISRG: Controlled Sideways Patterns Ahead of EarningsThe Medical Instruments and Supplies industry had stellar growth until 2022, when it could not beat that anomaly in revenue growth which was one of the primary reasons for the intermediate-term correction in 2022. 2023 patterned out the abnormal revenues and earnings for most industries that benefited from either the pandemic or from the government OVER-stimulation of the US economy via mega amounts of stimulus checks to WORKING people. Stimulus checks should have been allocated to the unemployed only. That would have lessened the impact of the resulting anomalies. If anyone had bothered to study pandemic history, the impact would have been much less severe for American families and the economy. As with hundreds of stocks at this time, NASDAQ:ISRG is trending sideways. This is not a perfect platform yet, but the sideways action has some of the traits of a platform such as consistent highs and lows from the perspective of a weekly chart. The stock is above its previous all-time high now, which provides a technical support level. The weekly chart shows that there has been Dark Pool accumulation and professional traders in the mix. IF the earnings report next week shows steady growth in both revenues and earnings in the 1st quarter, and IF the CEO's projections are positive, the stock could have an HFT gap up. If there was a negative surprise coming, the CEO should have warned by now. HFTs can make mistakes and gap it down. But if HFTs trade it down, then the stock price will immediately run back up into that sideways price level. If the report indicates a flat or minor improvement, then it is likely to remain within the sideways trend for another quarter. A controlled entry above the highs of the current sideways action eliminates that risk factor for either swing trading or position trading.
NASDAQ:ISRG
by MarthaStokesCMT-TechniTrader
Strong buyWe were stuck in the trading channel last week between 1.63000 and 1.64000. I have pinpointed my strong buy sentiment on the charts. All very clear indications that the pair should continue towards top resistance and possibly breach to retest a new top resistance before reversal (most likely right at a whole number :) ). On the contrary we could see a significant breach following the second up trend after the first sideways breakout out following a downtrend. Please comment with your thoughts and added ideas! Thank you and let’s crush this week!
Long
by Pika7993
4